Skip to content
2000
Volume 10, Issue 6
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

To be able to produce advanced therapy medicinal products, compliance with regulatory standards while maintaining flexibility is mandatory. For this purpose, careful planning is vital in the design or upgrade of a facility. Similarly, extensive foresight is elemental to anticipate upcoming needs and requirements. Failing this may lead to the facility's inability to meet the demands. In this chapter we aim to outline the current issues with regards to the European Union Directives (EUD) on advanced therapies, which impact gene and cell therapy facilities in Europe. This chapter is an attempt to elucidate what the minimum requirements for GMP facilities for gene and cell therapy products are and what is considered necessary to comply with the regulations in Europe.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/156652310793797757
2010-12-01
2024-12-23
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/156652310793797757
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test